Treatment of interdigital foot Erythrasma with ozonated olive oil

Main Article Content

Lourdes Ramírez-Hobak
Gabriela Moreno-Coutiño
Roberto Arenas-Guzmán
Alicia Gorzelewski
Ramón Fernández-Martínez

Keywords

Erythrasma, Ozone, Therapeutics, Photochemical oxidants

Abstract

Background: Erythrasma is caused by Corinebacterium minutissimum producing a porphyrin that with Wood’s light emits a coral-red fluorescence. It is the most common bacterial infection of the feet. Ozonated olive oil decreases the cytoplasm and damages bacterial proteins and lipids. Treatment is with oral erythromycin and there is no consensus regarding the topical therapy of choice. The aim of this paper is to evaluate the therapeutic efficacy of ozonated olive oil in a pilot trial for Erythrasma. 

Methods: Experimental, open, observational, descriptive, longitudinal clinical trial at the section of Mycology, of the General Hospital “Dr. Manuel Gea González”. Patients: 10 individuals with interdigital feet Erythrasma. Intervention: ozonated olive oil every 12 hours for 10 days was given. 

Results: All patients had disappearance of coral-red fluorescence, erythema, fissures, pruritus, and maceration; two patients persisted with scaling. A cure was obtained in 100 % of patients, similar to oral erythromycin response. 

Conclusions: Ozonated olive oil is a good topical treatment option for interdigital Erythrasma avoiding oral medications. Larger studies are required.

Abstract 757 | PDF (Spanish) Downloads 142 HTML (Spanish) Downloads 724 PubMed (Spanish) Downloads 0 HTML Downloads 878

References

Chodkiewicz HM,Cohen PR. Erythrasma: successful treatment after single-dose-clarithromycin. Int J Dermatol 2013;52(4):516-518.

 

Blaise G, Nikkels AF, Hermanns-Lê T, Nikkels-Tassoudji N, Piérard GE. Corynebacterium-associated skin infections. Int J Dermatol 2008;47(9):884-890.

 

Morales-Trujillo ML, Arenas R, Arroyo S. [Interdigital erythrasma: clinical, epidemiologic, and microbiologic findings]. Actas Dermosifiliogr 2008;99(6):469-473.

 

Holdiness M. Managment of cutaneous eritrasma. Drugs 2002;62(8):1131-1141.

 

Avci Oktay. A comparison between the effectiveness of erythromycin, single-dose clarithromycin and topical fusidic acid in the treatment of erythrasma. J Dermatolog Treat 2013;24:70-74.

 

Bocci V. Scientific and medical aspects of ozone therapy. State of the art. Arch Med Res 2006;37(4): 425-435.

 

Falcón-Lincheta L, Menéndez-Cepero S, Daniel-Simón R, Garballo-Otaño E, Moya-Duque S, Abreu-García M. Aceite ozonizado en Dermatología. Experiencia de 9 años. CENIC Ciencias Biológicas 1998; 29(3):192-195.

 

Valacchi G, Fortino V, Bocci V. The dual action of ozone on the skin, topical review. Br J Dermatol 2005; 153(6):1096-1100.

 

Bocci VA. Tropospheric ozone toxicity vs. usefulness of ozone therapy. Arch Med Res 2007;38(2):265-267.

 

Travagli V, Zanardi I, Valacchi G, Bocci V. Ozone and ozonated oils in skin diseases: a review. Mediators Inflamm 2010;2010:1-9.

 

Lezcano I, Núñez N, Gutiérrez M, Molerio J, Regüeiferos MG, Díaz W. Actividad in vitro del aceite de girasol ozonizado (OLEOZON) frente a diferentes especies bacterianas. CIENIC Ciencias biológicas 1996;27(1-3):46-49.

 

Curtiellas V, Gómez M, Ledea O, Fernández I, Sánchez E. Actividad antimicrobiana del OLEOZON sobre Staphylococcus aureus y Pseudomonas aeruginosa. CENIC Ciencias Biológicas 2005;36. Número especial.

 

Curtiellas V, Ledea O, Rodríguez S, Ancheta O, Echevarría M, Sánchez E et al. El OLEOZON sobre la viabilidad, la permeabilidad celular y la ultraestructura de Staphylococcus aureus. CENIC Ciencias Biológicas 2008;39(2):128-131.

 

Menéndez S, Fernández M, Amoroto M, Uranga R, Acuña P, Benítez JE et al. Eficacia y seguridad del OLEOZON tópico en el tratamiento de pacientes con impétigo. Rev Panam Infectol 2007;9(2):23-29.